USE OF LETERMOVIR AS CYTOMEGALOVIRUS INFECTION PROPHYLAXIS IN GENE THERAPY FOR WISKOTT-ALDRICH SYNDROME: PRELIMINARY SINGLE-CENTER EXPERIENCE (ESPID 2025) - May 25, 2025 - Abstract #EV0088; Pres time: May 27, 2025; Location: E-POSTER AREA; "Both patients had experienced CMV infection but obtained viral load negativization before GT; one of them also required therapy with valganciclovir. At observed timepoints, GT engraftment and outcome did not differ from other patients. We therefore confirmed that letermovir is effective and safe in lentiviral GT; furthermore, our data suggest that it doesn't affect in vivo GT engraftment nor disease correction."
Clinical • Gene therapy • Cytomegalovirus Infection • Human Immunodeficiency Virus • Infectious Disease
|
|
Sabina Cenciarelli; Federico Fraschetta; Salvatore Recupero; Giulia Consiglieri; Federica Barzaghi; Francesca Tucci; Valeria Calbi; Maddalena Migliavacca; Mariam Datukishvili; Carmen Caputo; Davide Sala; Maria Ester Bernardo; Maria Pia Cicalese; Alessandro Aiuti; Francesca Ferrua
|